Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Recruiting · NCT06023641 · Registry updated 2026-06-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, myomatous neoplasm, neoplasm, rhabdomyosarcoma, sarcoma | Recruiting | Phase 2 | 2026-06-15 | NCT06023641 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| St. Jude Children's Research Hospital | 169 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cook Children's Medical Center | Fort Worth | United States | 1 |
| St. Jude Children's Research Hospital | Memphis | United States | 194 |
| Stanford University | Palo Alto | United States | 161 |